ArticleNoro psikiyatri arsivi2026
Non-Motor Symptoms in Myasthenia Gravis Patients: Evaluation of Auditory and Olfactory Functions.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Myasthenia gravis (MG) is an autoimmune disease characterized by conduction defects at the neuromuscular junction. Recent studies suggest that impairment in acetylcholine neurotransmission occurs not only at the neuromuscular junction but also in the central and peripheral nervous systems. In this context, we aimed to investigate the presence of auditory and olfactory dysfunction, which are non-motor symptoms (NMS), alongside motor symptoms in patients with MG. Methods: A total of 30 MG patients and 30 healthy controls were enrolled in the study. Demographic characteristics of all participants were recorded. Olfactory functions were assessed using the Connecticut Chemosensory Clinical Research Center (CCCRC) test, while auditory functions were evaluated through pure tone audiometry (PTA) and tympanometric assessment. Additionally, patients were evaluated with MG Foundation of America (MGFA) Clinical Classification, MG-Composite scoring (MGC) and MG-Quality of Life Questionnaire 15-item scale Turkish version (MG-QOL15-T). Results: No statistically significant difference was found between the MG and control groups for the n-Butanol threshold test score, identification test score, and total test score, which are components of the CCCRC test. There was no significant correlation between the age of disease onset and olfactory scores. A statistically significant moderate negative correlation was found between disease duration and both identification and total olfactory scores (r=-0.447, p=0.013 and r=-0.374, p=0.042, respectively). In the PTA test, the hearing threshold at 2000 Hz frequency in the right ear of patients was higher compared to the control group, and this difference was found to be statistically significant. No association was found between the patients' olfactory and auditory functions with the MG-QOL15- T. Conclusion: This study suggests partial impairment in olfactory and auditory functions, NMS, in MG patients; however, these findings do not seem to effect the patients' quality of life. It should be considered that MG may be accompanied not only by motor symptoms but also by NMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.